The startup develops therapies targeting molecular processes associated with autism spectrum disorder and attention deficit hyperactivity disorder, utilizing drug discovery services focused on natural products. Their approach aims to enhance brain function and prevent developmental disorders, providing medical professionals with effective treatment options.
Funding
$880K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for neurodevelopmental disorders like Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD) often only address comorbid symptoms, lacking therapies that target the underlying pathological mechanisms. This results in a significant unmet medical need for effective treatments that can improve core symptoms and overall brain function.
Solution
NeuroVenti is a biotech company focused on developing novel therapeutics for neurodevelopmental disorders, including ASD and ADHD, by targeting the underlying molecular mechanisms. The company utilizes a precision multi-target approach to drug discovery, aiming to create first-in-disease treatments with superior efficacy and reduced side effects. NeuroVenti's pipeline includes small molecule drugs and electroceutical approaches, with lead candidates in preclinical and clinical stages, including a Phase 2 clinical trial for their ASD candidate NV01-A02. In addition to drug development, NeuroVenti offers non-clinical contract research and development organization (CDRO) services, providing customized solutions for preclinical evaluation of efficacy and safety for candidate molecules targeting CNS disorders.
Target Audience
NeuroVenti's primary customers include individuals with ASD, ADHD, and related neurodevelopmental disorders, as well as pharmaceutical and biotech companies seeking preclinical R&D services for CNS-targeting therapeutics.
Features
- Pipeline of multi-target drugs designed for precision action in neurodevelopmental disorders
- NV01-A02: Lead candidate for ASD and Fragile X Syndrome (FXS), with FDA Orphan Drug Designation for FXS treatment, currently in Phase 2 clinical trials
- NV01-A03: Drug repurposing strategy for ASD, preparing for Phase 2 overseas clinical trials
- NV01-062: New Chemical Entity (NCE) with multiple new targets for ASD, undergoing preclinical efficacy and toxicity testing
- NV01-E01: Electroceutical approach for ASD, in exploratory clinical trials, with a combined administration protocol with chemical drugs
- Non-clinical CDRO services: Customized preclinical research consulting, CNS disease-related research services, and in vitro & in vivo efficacy testing
- AI-based 3D automated behavior analysis system for in vivo efficacy evaluation
- In vitro efficacy evaluation & MOA research platform, including primary cell culture models, cell lines, neuronal cell death & neurite outgrowth assays, and neurotransmitter change analysis
- Adverse effect & addiction verification platform, including receptor binding assays, mental and physical dependence testing, and sleep disturbance analysis